The allergy immunotherapy market is expanding at a considerable speed due to high prevalence and increase in incidences of allergies across the globe. The global allergy immunotherapy market was expected to be at US$ xx Bn in 2018 and is projected to expand at CAGR of xx% from 2018 to 2026 to exceed the US$xxx Bn by 2026. The global allergy immunotherapy expansion is attributed to the increase in awareness regarding allergy treatment, the launch of new products, and rapidly growing allergic population. According to a report that was published by the World Health Organization (WHO), nearly 10-40% of the population were affecting with allergy in 2013.
The high prevalence and incidence rate of allergy across the globe are the major drivers of the global allergy immunotherapy market. In addition, an increase in awareness about the treatment of allergy and high clinical R&D budget by governments and non-profit organizations are expected to fuel the allergy immunotherapy market during the forecast period. Promising product pipeline are creating opportunities for business development during the forecast period. Across the world, there found around 10 different drugs in phase-3 of the clinical pipeline studies to treat different allergy symptoms.
The subcutaneous immunotherapy (SCIT) is a widely used and effective form of allergy immunotherapy. This SCIT treatment alters the immune system, thereby prevents the development of new allergies and asthma. Allergy tablets are a type of sublingual immunotherapy (SLIT) that treats certain allergies. These allergy tablets are going to decrease the symptoms by helping the body to build resistance against allergen effects. Anyway, tablets can only treat a single type of allergen and cannot avoid the development of new allergies and asthma. The US Food and Drug administration (FDA) in 2014 has approved SLIT tablets for treating ragweed and grass pollen allergies. The recent approval by the US FDA and the launch of new therapies including Oralair, Grastek, and Ragwitek in 2014 had an impact on the sublingual therapy market in 2016.
The allergy immunotherapy market is divided into four segments based on treatment type, allergy type, distribution channel, and geography.
Treatment type: SCIT and SLIT. SCIT was dominating the global allergy immunotherapy market in 2016. The segment is shown to expand at a moderate pace and gain market share during the forecast period.
Allergy type: Allergic rhinitis, food allergy, asthma, venom allergy, and others. The allergic rhinitis segment holds the leading share in the global market. The asthma segment accounted for a significant market share because of the effectiveness of SCIT and SLIT in treating allergic asthma. The other segment includes allergies like latex allergy, pollen allergy, and mold allergy.
Distribution channels: Hospital pharmacies, retail pharmacies & drug stories, and online pharmacies. Hospital pharmacies are expected to dominate the global allergy immunotherapy market.
Geographically: North America, Asia Pacific, Europe, America, and the Middle East & Africa. Europe holds the largest share of the global allergy immunotherapy market owing to its large patient population, followed by North America. The region is known to be highly attractive and is expected to expand at a significant CAGR during the forecast period. The Asia Pacific market is expected to expand at a moderate growth rate. Majority of the allergy immunotherapy market share is captured by Japan and China in the Asia-Pacific region, due to the presence of a huge allergic population in these countries.
Major players involved in the allergy immunotherapy market are Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Aimmune Therapeutics, Merck KGaA (Allergopharma), HAL Allergy Group, DBV Technologies, Circassia, Biomay AG, and Anergis.
Report Description: The report covers in-depth analysis on Allergy Immunotherapy Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by application (Allergic rhinitis, food allergy, asthma, venom allergy, and others). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Allergy Immunotherapy Market. The company profile includes key information on overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.